Table 2.
Differentially expressed genes in PC-treated via untreated OA meniscal cells.
| Biological process |
Gene name |
Gene ID | Differential expression* |
Description |
|---|---|---|---|---|
| FGF receptor signaling pathway | FGF9 | NM_002010 | 2.38 | Fibroblast growth factor 9 (glia-activating factor) |
| FGFR2 | M87771 | 2.20 | Fibroblast growth factor receptor 2 | |
| FGF7 | NM_002009 | 1.83 | Fibroblast growth factor 7 (keratinocyte growth factor) | |
| NDST1 | AL526632 | 1.71 | N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 | |
| THBS1 | AI812030 | 1.68 | Thrombospondin 1 | |
| HHIP | AK098525 | −3.28 | Hedgehog interacting protein | |
| FGF18 | BC006245 | −1.73 | Fibroblast growth factor 18 | |
|
| ||||
| Collagen fibril organization | COL14A1 | M64108 | 2.06 | Collagen, type XIV, alpha 1 |
| COL11A1 | J04177 | 1.82 | Collagen, type XI, alpha 1 | |
| COL1A1 | AI743621 | 1.62 | Collagen, type I, alpha 1 | |
| SERPINH1 | NM_004353 | 1.66 | Serpin peptidase inhibitor, clade H, member 1 | |
| DPT | AI146848 | 1.65 | Dermatopontin | |
| TRAM2 | BC028121 | 1.60 | Translocation-associated membrane protein 2 | |
| COL5A1 | AI983428 | 1.52 | Collagen, type V, alpha 1 | |
| COL5A2 | NM_000393 | 1.44 | Collagen, type V, alpha 2 | |
|
| ||||
| Extracellular structure organization | CACNA1A | NM_023035 | 2.55 | Calcium channel, voltage dependent, P/Q type, alpha 1A subunit |
| COL14A1 | M64108 | 2.06 | Collagen, type XIV, alpha 1 | |
| ECM2 | NM_001393 | 2.04 | Extracellular matrix protein 2, female organ, and adipocyte specific | |
| MYO6 | AA877789 | 1.98 | Myosin VI | |
| TMPRSS6 | AI912086 | 1.96 | Transmembrane protease, serine 6 | |
| COL11A1 | J04177 | 1.82 | Collagen, type XI, alpha 1 | |
| CRISPLD2 | AL136861 | 1.74 | Cysteine-rich secretory protein LCCL domain containing 2 | |
| HSD17B12 | BC012536 | 1.68 | Hydroxysteroid (17-beta) dehydrogenase 12 | |
| SERPINH1 | NM_004353 | 1.66 | Serpin peptidase inhibitor, clade H, member 1 | |
| DCN | AI336924 | 1.65 | Decorin | |
| DPT | AI146848 | 1.65 | Dermatopontin | |
| COL1A1 | AI743621 | 1.62 | Collagen, type I, alpha 1 | |
| APLP1 | U48437 | 1.61 | Amyloid beta (A4) precursor-like protein 1 | |
| NFASC | AI821777 | −1.99 | Neurofascin homolog (chicken) | |
| MMP9 | NM_004994 | −1.91 | Matrix metallopeptidase 9 | |
|
| ||||
| Inflammatory response | ADORA1 | NM_000674 | 2.48 | Adenosine A1 receptor |
| CD24 | L33930 | 2.09 | CD24 molecule | |
| BCL6 | S67779 | 1.98 | B-cell CLL/lymphoma 6 | |
| NGF | NM_002506 | 1.84 | Nerve growth factor (beta polypeptide) | |
| CFD | NM_001928 | 1.82 | Complement factor D (adipsin) | |
| ITGB2 | NM_000211 | 1.80 | Integrin, beta 2 | |
| CFI | BC020718 | 1.74 | Complement factor I | |
| NDST1 | AL526632 | 1.71 | N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 | |
| IL17C | AF152099 | 1.70 | Interleukin 17C | |
| THBS1 | AI812030 | 1.68 | Thrombospondin 1 | |
| SERPINA3 | NM_001085 | 1.67 | Serpin peptidase inhibitor, clade A, member 3 | |
| AGTR1 | NM_004835 | 1.65 | Angiotensin II receptor, type 1 | |
| TFRC | N76327 | 1.64 | Transferrin receptor (p90, CD71) | |
| PDPN | AW590196 | 1.61 | Podoplanin | |
| MASP1 | AI274095 | 1.61 | Mannan-binding lectin serine peptidase 1 | |
| NFKBIZ | BE646573 | −2.58 | NFKb inhibitor, zeta | |
| ANXA1 | AU155094 | −2.47 | Annexin A1 | |
| ADRB2 | NM_000024 | −2.41 | Adrenergic, beta-2, receptor, surface | |
| SMAD1 | NM_015583 | −2.19 | SMAD family member 1 | |
| CXCL6 | NM_002993 | −2.19 | Chemokine (C-X-C motif) ligand 6 | |
| C2 | NM_000063 | −2.18 | Complement component 2 | |
| BMPR1B | AA935461 | −1.93 | Bone morphogenetic protein receptor, type IB | |
| TNFRSF1B | NM_001066 | −1.74 | Tumor necrosis factor receptor superfamily, member 1B | |
| EDNRA | NM_001957 | −1.67 | Endothelin receptor type A | |
| PLA2G4A | M68874 | −1.61 | Phospholipase A2, group IVA (cytosolic, calcium dependent) | |
| GPR68 | AI805006 | −1.60 | G protein-coupled receptor 68 | |
*Negative number indicates decreased expression and positive number indicates elevated expression (fold change) in PC-treated OA meniscal cells compared with untreated OA meniscal cells.